The Caisse nationale de l'assurance maladie (CNAM), France's national health insurance fund, has deployed artificial intelligence for healthcare fraud detection through data mining and scoring algorithms. CNAM administers France's compulsory health insurance system, covering approximately 68 million beneficiaries and processing very large volumes of reimbursement claims, provider invoices, prescriptions, and supporting administrative records through the Assurance Maladie network.
Within that operational environment, fraud detection is not framed as a small pilot or a narrow technical experiment. The retained sources describe a mature anti-fraud function embedded in routine health-insurance administration. CNAM uses automated scoring and pattern-analysis tools to identify atypical billing behaviour among healthcare providers, suspicious reimbursement claims, and documentary anomalies that merit closer review by fraud investigators. The documented targets include falsified prescriptions, phantom billing, duplicate billing, irregular invoicing practices, and organised fraud in provider networks. This places the case squarely in the implementation and accountability layer of social insurance administration rather than in eligibility determination for beneficiaries.
The available reporting indicates that CNAM's approach combines large-scale automated screening with substantial human investigation capacity. The system analyses claims histories, provider billing records, prescription activity, beneficiary utilisation patterns, and related administrative signals in order to prioritise files for review. Those signals are then taken up by dedicated anti-fraud staff rather than being allowed to trigger sanctions automatically. The retained evidence points to approximately 1,600 anti-fraud agents in 2025, alongside six interregional judicial investigation units (Piej) and a specialised UCIFE unit with cybercrime authority. In practical terms, that means the AI and scoring layer functions as an investigative triage mechanism inside a broader enforcement apparatus, not as a fully autonomous decision-maker.
The scale of the reported outcomes is material. According to the Fondation IFRAP source retained in this file, CNAM identified and stopped EUR 628 million in fraudulent claims in 2024, up 35 per cent from the EUR 466.6 million recorded in 2023. The same source reports an additional EUR 263 million in fraud prevented or avoided, a 55 per cent year-on-year increase. It also reports roughly 20,000 legal actions in 2024, up 91.3 per cent, and EUR 50 million in financial penalties, up 109.4 per cent. Those figures do not by themselves prove that every detected case came from a single AI model, but they do show that algorithmically assisted fraud control is operating at meaningful institutional scale inside the national health insurance system.
A more concrete operational example is the Asafo-Pharma tool cited in the retained sources. This tool is described as helping pharmacists identify forged prescriptions, and in 2024 it reportedly contributed to stopping 13.4 million fraudulent pharmacy transactions. That is important because it shows the anti-fraud system is not limited to background analytics on historical claims. At least part of the fraud-control architecture is embedded closer to frontline transaction points, where suspicious prescriptions and reimbursement attempts can be challenged before losses fully materialise.
A second example comes from the CPAM of Paris, which since August 2025 has used an experimental AI tool focused on fraud in the optical and hearing-aid sectors. The Acuité source says the system analyses suspicious documents such as falsified prescriptions and fake invoices. During its testing phase, it reportedly detected 125 cases of fraud and prevented hundreds of thousands of euros in losses. This sector-specific deployment suggests that CNAM's anti-fraud infrastructure is not static. Instead, it appears to be extended and adapted where existing controls leave residual vulnerabilities, especially in domains where documentary manipulation is prevalent.
The sources also show how automated detection links to real enforcement action. In April 2025, Assurance Maladie announced the deconventioning of seven health centres belonging to one network across six departments for four to five years. That press release is useful not because it discloses model architecture, which it does not, but because it demonstrates the real-world consequences of the fraud detection and investigation pipeline. Flagged cases can culminate in sanctions affecting provider participation in the public insurance system, which is why this case is coded as high decision criticality even though the final action is taken by human investigators and enforcement authorities.
At the same time, the evidence base has limits and the description is intentionally conservative. The retained sources support claims about data mining, scoring, fraud typologies, enforcement outputs, and specific sectoral tools, but they do not disclose the precise model families, training methodology, hosting environment, vendor stack, or formal algorithmic impact assessments. Legacy references to inaccessible or unconfirmed ISSA and OECD materials were therefore excluded from the scoped narrative. What remains is a source-bounded description of a confirmed production deployment: CNAM uses AI-assisted fraud detection and document analysis within its national health insurance anti-fraud operations, with large-scale screening feeding into human investigation and enforcement.